BERKELEY, Calif.– At the ATS 2025 International Conference in San Francisco, IMVARIA Inc. presented new multi-site clinical experience data highlighting real-world use of its AI-powered diagnostic service, Fibresolve, the first FDA-authorized adjunctive AI diagnostic tool for lung fibrosis. The service is being used by pulmonologists across the U.S. to support the evaluation of suspected Interstitial Lung Disease (ILD) and Idiopathic Pulmonary Fibrosis (IPF), with data from leading institutions such as Massachusetts General Hospital being shared at the conference.
Fibresolve, developed by physicians with software engineering backgrounds, represents a significant advancement in how artificial intelligence is applied in respiratory diagnostics. Rather than requiring clinics to implement complex systems or alter existing workflows, IMVARIA’s model allows physicians to refer cases to a centralized AI-powered service. The tool is designed to provide additional diagnostic insight in a non-invasive, workflow-friendly manner.
“We’re excited that our clinical users are sharing real-world experience with Fibresolve at the ATS Conference,” said Dr. Joshua Reicher, co-founder and CEO of IMVARIA. “As practicing physicians, my co-founder Dr. Michael Muelly and I built Fibresolve with the goal of making AI not only accurate and compliant with medical standards, but also simple for clinicians to use.”
Authorized by the FDA in early 2024, Fibresolve also holds the distinction of being the first AI diagnostic service with FDA Breakthrough Device designation and simultaneous CPT billing code adoption by the American Medical Association—an unprecedented milestone in the field of AI healthcare tools.
In addition to Fibresolve, IMVARIA is presenting clinical updates on two other AI solutions in its pulmonary portfolio. ScreenDx, which received FDA clearance in 2025, is the first AI tool specifically approved to assess lung imaging findings compatible with ILD. The company is also sharing early research on Bronchosolve, an investigational AI system designed to improve the evaluation of indeterminate lung nodules.
The ATS 2025 conference, which runs from May 16–21, brings together global leaders in pulmonary medicine, and IMVARIA’s presence highlights the growing role of AI in enhancing respiratory diagnostics and patient care.
